Iron, Inflammation, Dialysis Adequacy, Nutritional Status, and Hyperparathyroidism Modify Erythropoietic Response

被引:54
作者
Gaweda, Adam E. [1 ]
Goldsmith, Linda J. [2 ]
Brier, Michael E. [3 ]
Aronoff, George R.
机构
[1] Univ Louisville, Dept Med, Div Nephrol, Louisville, KY 40202 USA
[2] Univ Louisville, Sch Publ Hlth & Informat Sci, Louisville, KY 40202 USA
[3] Dept Vet Affairs, Louisville, KY USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2010年 / 5卷 / 04期
基金
美国国家卫生研究院;
关键词
ANEMIC HEMODIALYSIS-PATIENTS; LOW TRANSFERRIN SATURATION; HIGH SERUM FERRITIN; HEMOGLOBIN VARIABILITY; STIMULATING AGENTS; INTRAVENOUS IRON; EPOETIN-ALPHA; RESISTANCE; MORTALITY; REQUIREMENTS;
D O I
10.2215/CJN.04710709
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: The erythropoietic response in hemodialysis patients depends on several physiologic factors. Most epidemiologic studies include the effect of these factors by representing them as confounders. This study tested the hypothesis that iron stores, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism act as nonlinear effect modifiers of the erythropoietic response and quantified the magnitude of those effects over clinically relevant ranges. Design, setting, participants, & measurements: The following retrospective data from 209 hemodialysis patients receiving Epoetin alfa (Epo) were collected: monthly: predialysis hemoglobin (Hgb), transferrin saturation, serum albumin, dialysis adequacy (Kt/V); quarterly: predialysis serum ferritin and intact parathyroid hormone over a period of 13 to 69 months. The study analyzed the dynamic relationship between hemoglobin and Epo, considering nonlinear effect modification by ferritin, transferrin saturation, Kt/V, albumin, and parathyroid hormone individually. Results: Maximum Hgb response to Epo was achieved for serum ferritin between 350 and 500 ng/ml, transferrin saturation greater than 30%, Kt/V greater than 1.4, and albumin greater than 3.8 g/dl. Hgb sensitivity to Epo decreases by about 30% as parathyroid hormone increases from 0 through 1000 pg/ml. Conclusions: Serum ferritin, transferrin saturation, Kt/V, serum albumin, and intact parathyroid hormone are markers of nonlinear effect modification of the erythropoietic response in hemodialysis patients. Clin J Am Soc Nephrol 5: 576-581, (C) 2010. doi: 10.2215/CJN.04710709
引用
收藏
页码:576 / 581
页数:6
相关论文
共 30 条
[1]   Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients [J].
Agarwal, Rajiv ;
Davis, Joyce L. ;
Smith, Linda .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (01) :98-104
[2]   THE MODERATOR MEDIATOR VARIABLE DISTINCTION IN SOCIAL PSYCHOLOGICAL-RESEARCH - CONCEPTUAL, STRATEGIC, AND STATISTICAL CONSIDERATIONS [J].
BARON, RM ;
KENNY, DA .
JOURNAL OF PERSONALITY AND SOCIAL PSYCHOLOGY, 1986, 51 (06) :1173-1182
[3]  
Bates D., 2009, Mixed-Effects Models in S and S-PLUS
[4]  
Besarab A, 2000, J AM SOC NEPHROL, V11, P530, DOI 10.1681/ASN.V113530
[5]  
Besarab A, 2001, Nephrol Nurs J, V28, P429
[6]   Association of Hemoglobin Variability and Mortality among Contemporary Incident Hemodialysis Patients [J].
Brunelli, Steven M. ;
Lynch, Katherine E. ;
Ankers, Elizabeth D. ;
Joffe, Marshall M. ;
Yang, Wei ;
Thadhani, Ravi I. ;
Feldman, Harold I. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (06) :1733-1740
[7]   Challenging the boundaries of anemia management: a balanced approach to i.v. iron and EPO therapy [J].
Coyne, D .
KIDNEY INTERNATIONAL, 2006, 69 :S1-S3
[8]  
COYNE D, 2006, KIDNEY INT S, pS13
[9]   Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study [J].
Coyne, Daniel W. ;
Kapoian, Toros ;
Suki, Wadi ;
Singh, Ajay K. ;
Moran, John E. ;
Dahl, Naomi V. ;
Rizkalal, Adel R. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (03) :975-984
[10]   Inflammation and resistance to treatment with recombinant human erythropoietin [J].
Del Vecchio, L ;
Pozzoni, P ;
Andrulli, S ;
Locatelli, F .
JOURNAL OF RENAL NUTRITION, 2005, 15 (01) :137-141